메뉴 건너뛰기




Volumn 23, Issue 9, 2012, Pages 2306-2313

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with epcampositive relapsed or refractory advanced-stage breast cancer

Author keywords

Adecatumumab; Docetaxel; Epcam; Metastatic breast cancer; Mt201

Indexed keywords

ADECATUMUMAB; DOCETAXEL; EPITHELIAL CELL ADHESION MOLECULE;

EID: 84865535404     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr625     Document Type: Article
Times cited : (42)

References (23)
  • 1
    • 77953744331 scopus 로고    scopus 로고
    • Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975
    • La Vecchia C, Bosetti C, Lucchini F et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010; 21: 1323-1360.
    • (2010) Ann Oncol , vol.21 , pp. 1323-1360
    • La Vecchia, C.1    Bosetti, C.2    Lucchini, F.3
  • 2
    • 0024337144 scopus 로고
    • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    • Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
    • (1989) Science , vol.244 , pp. 707-712
    • Slamon, D.J.1    Godolphin, W.2    Jones, L.A.3
  • 3
    • 4143065769 scopus 로고    scopus 로고
    • The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation
    • Munz M, Kieu C, Mack B et al. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004; 23: 5748-5758.
    • (2004) Oncogene , vol.23 , pp. 5748-5758
    • Munz, M.1    Kieu, C.2    Mack, B.3
  • 4
    • 4143074922 scopus 로고    scopus 로고
    • EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy
    • Osta WA, Chen Y, Mikhitarian K et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004; 64: 5818-5824.
    • (2004) Cancer Res , vol.64 , pp. 5818-5824
    • Osta, W.A.1    Chen, Y.2    Mikhitarian, K.3
  • 5
    • 4043147142 scopus 로고    scopus 로고
    • High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer
    • Spizzo G, Went P, Dirnhofer S et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004; 86: 207-213.
    • (2004) Breast Cancer Res Treat , vol.86 , pp. 207-213
    • Spizzo, G.1    Went, P.2    Dirnhofer, S.3
  • 6
    • 53249097862 scopus 로고    scopus 로고
    • Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer
    • Schmidt M, Hasenclever D, Schaeffer M et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 2008; 14: 5849-5855.
    • (2008) Clin Cancer Res , vol.14 , pp. 5849-5855
    • Schmidt, M.1    Hasenclever, D.2    Schaeffer, M.3
  • 7
    • 78649772250 scopus 로고    scopus 로고
    • Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases
    • Cimino A, Halushka M, Illei P et al. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat 2010; 123: 701-708.
    • (2010) Breast Cancer Res Treat , vol.123 , pp. 701-708
    • Cimino, A.1    Halushka, M.2    Illei, P.3
  • 8
    • 79151486669 scopus 로고    scopus 로고
    • Ep-CAM RNA expression predicts metastasis free survival in three cohorts of untreated node-negative breast cancer
    • Schmidt M, Petry IB, Böhm D et al. Ep-CAM RNA expression predicts metastasis free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Res Treat 2011; 125: 637-646.
    • (2011) Breast Cancer Res Treat , vol.125 , pp. 637-646
    • Schmidt, M.1    Petry, I.B.2    Böhm, D.3
  • 9
    • 0036643516 scopus 로고    scopus 로고
    • In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment
    • Naundorf S, Preithner S, Mayer P et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 2002; 100: 101-110.
    • (2002) Int J Cancer , vol.100 , pp. 101-110
    • Naundorf, S.1    Preithner, S.2    Mayer, P.3
  • 10
    • 77951881160 scopus 로고    scopus 로고
    • An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
    • Schmidt M, Scheulen ME, Dittrich C et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 2010; 21: 275-282.
    • (2010) Ann Oncol , vol.21 , pp. 275-282
    • Schmidt, M.1    Scheulen, M.E.2    Dittrich, C.3
  • 11
    • 78650991636 scopus 로고    scopus 로고
    • Phase II study of the human antiepithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy
    • Marschner N, Rüttinger D, Zugmaier G et al. Phase II study of the human antiepithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. Urol Int 2010; 85: 386-395.
    • (2010) Urol Int , vol.85 , pp. 386-395
    • Marschner, N.1    Rüttinger, D.2    Zugmaier, G.3
  • 13
    • 9344222778 scopus 로고    scopus 로고
    • ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas
    • de Bono JS, Tolcher AW, Forero A et al. ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 2004; 10: 7555-7565.
    • (2004) Clin Cancer Res , vol.10 , pp. 7555-7565
    • de Bono, J.S.1    Tolcher, A.W.2    Forero, A.3
  • 14
    • 33748956628 scopus 로고    scopus 로고
    • A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients
    • Oberneder R, Weckermann D, Ebner B et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer 2006; 42: 2530-2538.
    • (2006) Eur J Cancer , vol.42 , pp. 2530-2538
    • Oberneder, R.1    Weckermann, D.2    Ebner, B.3
  • 15
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 18
    • 0034083739 scopus 로고    scopus 로고
    • Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands
    • Kruijtzer CMF, Verweij J, Schellens JH et al. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands. Anticancer Drugs 2000; 11: 249-255.
    • (2000) Anticancer Drugs , vol.11 , pp. 249-255
    • Kruijtzer, C.M.F.1    Verweij, J.2    Schellens, J.H.3
  • 19
    • 0034912384 scopus 로고    scopus 로고
    • Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter community-based feasibility trial
    • Schmidinger M, Budinsky AC, Wenzel C et al. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial. Cancer Chemother Pharmacol 2001; 47: 57-62.
    • (2001) Cancer Chemother Pharmacol , vol.47 , pp. 57-62
    • Schmidinger, M.1    Budinsky, A.C.2    Wenzel, C.3
  • 20
    • 0032829692 scopus 로고    scopus 로고
    • Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience
    • Bonneterre J, Spielman M, Guastalla JP et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 1999; 35: 1431-1439.
    • (1999) Eur J Cancer , vol.35 , pp. 1431-1439
    • Bonneterre, J.1    Spielman, M.2    Guastalla, J.P.3
  • 21
    • 0032078891 scopus 로고    scopus 로고
    • Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer
    • Archer CD, Lowdell C, Sinnett HD et al. Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. Eur J Cancer 1998; 34: 816-819.
    • (1998) Eur J Cancer , vol.34 , pp. 816-819
    • Archer, C.D.1    Lowdell, C.2    Sinnett, H.D.3
  • 22
    • 18544373963 scopus 로고    scopus 로고
    • Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer
    • Massacesi C, Marcucci F, Boccetti T et al. Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. J Exp Clin Cancer Res 2005; 24: 43-48.
    • (2005) J Exp Clin Cancer Res , vol.24 , pp. 43-48
    • Massacesi, C.1    Marcucci, F.2    Boccetti, T.3
  • 23
    • 76949107605 scopus 로고    scopus 로고
    • Clinical outcomes of patients with breast cancer in a phase I clinic: the M D. Anderson Cancer Center Experience
    • Wheler J, Tsimberidou AM, Moulder S et al. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson Cancer Center Experience. Clin Breast Cancer 2010; 10: 46-51.
    • (2010) Clin Breast Cancer , vol.10 , pp. 46-51
    • Wheler, J.1    Tsimberidou, A.M.2    Moulder, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.